BATM Advanced Communications Ld Senior management appointments at Adaltis (8439J)
July 03 2017 - 1:00AM
UK Regulatory
TIDMBVC
RNS Number : 8439J
BATM Advanced Communications Ld
03 July 2017
3 July 2017
BATM Advanced Communications Limited
("BATM" or "the Group")
BATM Appoints Senior Management at Adaltis as it Widens Scope of
its Molecular Biology Platform
BATM Advanced Communications Limited (LSE: BVC), a leading
provider of real-time technologies for networking solutions and
medical laboratory systems, is pleased to announce that it is
appointing Dr. David Perry MD as Chief Executive Officer of Adaltis
S.R.L ("Adaltis") with immediate effect. Adaltis is a
majority-owned subsidiary of the Group that manufactures medical
diagnostic equipment. This is a new role created within Adaltis as
it gears up to take advantage of the advances made within its
molecular biology business unit as well as the growing in-vitro
diagnostics field. Also, as part of the restructuring of the senior
team, the Board of Adaltis is promoting the current General
Manager, Marco Spadaciolli, to Chief Operating Officer.
Dr. Perry has more than 20 years' international experience in
developing and bringing to global markets new medical devices, and
pharmaceutical and biotechnological products across multiple
therapy areas, and in small and large companies. Most recently he
served as Principal of Lilium Bioscience, a company dedicated to
bringing to market novel therapeutic and medical-device products in
the areas of biosurgery, orthopedics, regenerative medicine and
dermatology.
Prior to this, Dr. Perry headed the global clinical development
and medical services departments at Baxter Bioscience as their VP
Global Clinical and Medical Affairs. With operations around the
world and substantial investment in the development of innovative
therapies, Baxter is a major player in several biomedical areas
(www.baxter.com). Before Baxter, Dr. Perry established and headed
the European clinical research and medical affairs departments for
the Philadelphia-based biopharmaceutical company, Cephalon, at
their European headquarters in the UK. Prior to that, Dr. Perry
held a number of clinical R&D management positions, with
increasing scope and level of responsibilities, in a number
companies, including Ferring (Copenhagen, Denmark), Roche (Palo
Alto, California) and Novo Nordisk (Copenhagen, Denmark). Dr. Perry
received his M.D. from the Ben-Gurion University in Israel and did
his training at the Hadassah University Hospital in Jerusalem,
Israel. Dr. Perry is a fellow of the Royal Society of Medicine and
a member of the American Society of Hematology.
Dr. Zvi Marom, CEO of BATM, said: "We are delighted to have
David join Adaltis. We believe that Adaltis is maturing to be an
important player in the in-vitro diagnostic field and is making the
necessary steps to achieve that. We look forward to leveraging
David's experience as we take Adaltis to the next stage of its
development."
Enquiries:
BATM Advanced Communications
--------------------------------------- -----------------
Dr Zvi Marom, Chief Executive Officer +972 9866 2525
--------------------------------------- -----------------
Moti Nagar, Chief Financial Officer
--------------------------------------- -----------------
finnCap
--------------------------------------- -----------------
Stuart Andrews, Scott Mathieson +44 20 7220 0500
--------------------------------------- -----------------
Shore Capital
--------------------------------------- -----------------
Mark Percy, Anita Ghanekar +44 20 7408 4050
--------------------------------------- -----------------
Luther Pendragon
--------------------------------------- -----------------
Harry Chathli, Claire Norbury +44 20 7618 9100
--------------------------------------- -----------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEANXAELXXEFF
(END) Dow Jones Newswires
July 03, 2017 02:00 ET (06:00 GMT)
Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart
From Apr 2024 to May 2024
Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart
From May 2023 to May 2024